All In Biotech

Drug Trial Radar · NCT05434897

A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

A Randomized, Double-blind, Placebo Self-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preventive Efficacy of AK3280 Cream After Cicatrectomy in Patients With Hypertrophic Scar in China.

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 8, 2022

Primary completion

Jul 18, 2023

Study completion Jul 18, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo self-controlled phase I/II clinical study to evaluate the safety, tolerability and preventive efficacy of different doses of AK3280 cream (AK3287 ) after cicatrectomy in Patients with Hypertrophic Scar in China.

Conditions

  • Hypertrophic Scar

Interventions

  • AK3280 CreamDrug

    Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

  • Placebo creamDrug

    Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of adverse events(AE)/ serious adverse events (SAEs)Time frame: Up to 14 weeks
  2. Number of participants with abnormal Skin ExaminationTime frame: Up to 14 weeks
  3. Number of participants with abnormal vital signsTime frame: Up to 14 weeks
  4. Number of participants with abnormal Physical examination findingsTime frame: Up to 14 weeks
  5. Number of participants with abnormal 12-lead ECG readingsTime frame: Up to 14 weeks
  6. Number of participants with abnormal laboratory test resultsTime frame: Up to 14 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Ninth People's Hospital,Shanghal JiaoTong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.